TABLE 3.
Pooled mean differences of different types of antihypertensive drugs on augmentation index. Upper right triangle gives the pooled mean differences from pairwise comparisons (column intervention relative to row), lower left triangle pooled mean differences from the network meta-analysis (row intervention relative to column). * Values p < 0.05 were considered significant.
| PB |
0.73
(0.22, 1.24) n1 = 1/n2 = 48 |
−0.24 (−0.60, 0.12) n1 = 2/n2 = 119 |
−1.32
(−2.42, −0.22) n1 = 4/n2 = 237 |
−1.00 (−2.61, 0.60) n1 = 2/n2 = 108 |
−0.25 (−0.73, 0.23) n1 = 1/n2 = 68 |
NA | NA | NA | NA | NA | NA | NA |
| −0.03 (−0.52, 0.47) |
BB | −0.47 (−1.20, 0.26) n1 = 1/n2 = 30 |
−0.28 (−0.87, 0.30) n1 = 5/n2 = 207 |
−0.36 (−0.73, 0.00) n1 = 2/n2 = 338 |
−1.20
(−1.75, −0.66) n1 = 2/n2 = 66 |
0.35 (−0.34, 1.03) n1 = 1/n2 = 52 |
NA | NA |
−0.39
(−0.58, −0.19) n1 = 4/n2 = 1071 |
NA | NA | NA |
| −0.36 (−0.89, 0.16) |
−0.33 (−0.85, 0.18) |
TD |
−0.37
(−0.72, -0.02) n1 = 2/n2 = 129 |
−0.83 (−2.51, 0.86) n1 = 2/n2 = 117 |
0.09 (−0.65, 0.46) n1 = 3/n2 = 132 |
NA | NA | NA |
−1.02
(−1.58, −0.46) n1 = 1/n2 = 28 |
NA | NA | NA |
|
−0.83
(−1.27, −0.38) |
−0.80
(−1.18, −0.42) |
−0.47 (−0.95, 0.02) |
ACEI | 0.39 (−0.19, 0.96) n1 = 3/n2 = 234 |
−0.15 (−0.59, 0.28) n1 = 3/n2 = 88 |
−0.14 (−0.49, 0.21) n1 = 2/n2 = 103 |
0.21 (−0.30, 0.71) n1 = 1/n2 = 58 |
NA | NA | NA | NA | NA |
|
−0.56
(−1.05, −0.08) |
−0.54
(−0.96, −0.11) |
−0.20 (−0.70, 0.30) |
0.26 (−0.12, 0.65) |
ARB | −0.02 (−0.22, 0.26) n1 = 2/n2 = 266 |
−0.29 (−1.02, 0.44) n1 = 1/n2 = 29 |
NA | NA | NA | −0.45 (−0.31, 1.21) n1 = 1/n2 = 39 |
NA | NA |
|
−0.63
(−1.17, −0.09) |
−0.60
(−1.09, -0.12) |
−0.27 (−0.80, 0.26) |
0.20 (−0.27, 0.66) |
−0.07 (−0.54, 0.41) |
CCB | NA | NA | NA | −1.33
(−1.91, −0.75) n1 = 1/n2 = 28 |
0.06 (−0.28, 0.40) n1 = 1/n2 = 144 |
NA | NA |
|
−0.73
(−1.44, −0.02) |
−0.71
(−1.32, −0.09) |
−0.37 (−1.10, 0.36) |
0.10 (−0.51, 0.70) |
−0.17 (−0.81, 0.47) |
−0.10 (−0.81, 0.61) |
RI | NA | NA | NA | NA | NA | NA |
| −0.73 (−2.08, 0.63) |
−0.70 (−2.03, 0.63) |
−0.37 (−1.73, 1.00) |
0.10 (−1.18, 1.38) |
−0.16 (−1.50, 1.17) |
−0.10 (−1.46, 1.26) |
−0.00 (−1.41, 1.42) |
AARA | NA | NA | NA | NA | NA |
| −0.19 (−1.44, 1.06) |
−0.16 (−1.36, 1.04) |
0.17 (−1.07, 1.42) |
0.54 (−0.57, 1.85) |
0.38 (−0.83, 1.58) |
0.44 (−0.76, 1.64) |
0.54 (−0.77, 1.86) |
0.54 (−1.22, 2.30) |
BB/TD | NA |
−0.90
(−1.62, −0.18) n1 = 2/n2 = 124 |
NA | NA |
|
−0.72
(−1.42, −0.02) |
−0.70
(−1.25, −0.14) |
−0.36 (−1.05, 0.33) |
0.11 (−0.52, 0.73) |
−0.16 (−0.80, 0.48) |
−0.09 (−0.75, 0.57) |
0.01 (−0.79, 0.81) |
0.01 (−1.42, 1.43) |
−0.53 (−1.72, 0.65) |
TD/ACEI | 0.02 (−0.60, 0.64) n1 = 1 / n2 = 40 |
−0.14 (−0.76, 0.48) n1 = 1/n2 = 40 |
0.01 (−0.61, 0.63) n1 = 1/n2 = 40 |
| −0.70 (−1.54, 0.13) |
−0.68 (−1.44, 0.08) |
−0.34 (−1.17, 0.48) |
0.12 (−0.65, 0.90) |
−0.14 (−0.91, 0.62) |
−0.07 (−0.83, 0.68) |
0.03 (−0.90, 0.96) |
0.02 (−1.47, 1.52) |
−0.52 (−1.45, 0.41) |
0.02 (−0.71, 0.74) |
TD/ARB | −0.14 (−0.76, 0.48) n1 = 1/n2 = 40 |
−0.16 (−0.34, 0.03) n1 = 2/n2 = 247 |
| −0.94 (−1.97, 0.10) |
−0.91 (−1.87, 0.05) |
−0.58 (−1.61, 0.45) |
−0.11 (−1.10, 0.88) |
−0.38 (−0.61, 1.36) |
−0.31 (−1.30, 0.68) |
−0.21 (−1.32, 0.90) |
−0.21 (−1.83, 1.40) |
−0.75 (−1.99, 0.49) |
−0.22 (−1.10, 0.66) |
−0.23 (−1.05, 0.59) |
ACEI/CCB | −0.14 (−0.57, 0.30) n1 = 2/n2 = 128 |
|
−0.98
(−1.95, −0.01) |
−0.95
(−1.85, −0.06) |
−0.62 (−1.58, 0.34) |
−0.15 (−1.07, 0.77) |
−0.42 (−1.33, 0.50) |
−0.35 (−1.26, 0.57) |
−0.25 (−1.30, 0.80) |
−0.25 (−1.83, 1.32) |
−0.79 (−1.96, 0.37) |
−0.26 (−1.07, 0.56) |
−0.27 (−0.97, 0.42) |
−0.04 (−0.78, 0.70) |
ARB/CCB |
n1 = trials; n2 = subjects.
AARA: Alpha-adrenergic receptor antagonists; ACEI: Angiotensin-converting enzyme inhibitors; ARB: Angiotensin receptor blockers; BB: beta-blockers; CCB: Calcium channel blockers; TD: thiazide diuretics; PB: placebo; RI: renin inhibitors.